Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

,023

Restricted cash 564,000 -

$11,065,520 $13,687,454

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

Accounts payable $324,890 $757,420

Accrued expenses 738,330 586,849

Current portion of term loan 85,831 80,047

Total current liabilities 1,149,051 1,424,316

Long-term portion of term loan 46,004 111,119

Total liabilities 1,195,055 1,535,435

Commitments and Contingencies

Stockholders' Equity

Preferred stock, authorized 5,000,000

shares, $.01 par value, none

issued or outstanding - -

Common stock, authorized 100,000,000

shares, $.001 par value, 41,130,270

and 40,991,385 issued and outstanding

as of September 30, 2008, and

December 31, 2007, respectively 41,130 40,991

Additional paid-in capital 70,879,940 69,945,666

Accumulated deficit (61,050,605) (57,834,638)

Total stockholders' equity 9,870,465 12,152,019

$11,065,520 $13,687,454

SCOLR Pharma, Inc.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Revenues

Licensing fees $- $- $- $173,077

Royalty
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Scientists at,deCODE genetics, Inc. (Nasdaq: DCGN ) ... version of a common single-letter variant in the ... impact on susceptibility to type 2,diabetes (T2D). The ... large, but unusual:,if an individual inherits it from ... more than 30% compared to those who inherit ...
(Date:12/16/2009)... Cohera Medical Inc. today announced the treatment of ... lead surgical adhesive product, TissuGlu®. Initiation of the ... progression of the lead product toward clinical practice. ... open-label, randomized study to investigate the safety of ... associated complications in abdominoplasty, or "tummy tuck," surgeries. ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
Breaking Medicine Technology:deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 213 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 113 Bay Area Breast Cancer Survivors Showcased Fabulously in the New 2010 Pinups for Purpose Calendar 59842 2Red Cross Strives to Help Disasters Vulnerable Population 59839 1Red Cross Strives to Help Disasters Vulnerable Population 59839 2Red Cross Strives to Help Disasters Vulnerable Population 59839 3Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 1Healthcare Realty Trust Announces Third Quarter Earnings Release Date and Conference Call 59836 2
... presented at ICAAC -, BRIDGEWATER, N.J., Sept. ... open-label Phase 3 study showed that 84 percent ... of,PREZISTA(TM) (darunavir) 800 mg (two 400 mg tablets) ... and tenofovir disoproxil,fumarate) reached an undetectable viral load ...
... 18 - A,multi-disciplinary group of researchers from the ... Maryland Biotechnology Institute (UMBI),has won a competitive, $2 ... way researchers develop and test pharmaceutical drugs., ... Distinguished,Professor and chair of the Fischell Department of ...
Other Medicine Technology:New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 2New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 3New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 4New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 5New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 6New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy 7U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
(Date:12/16/2009)... New Enterprise Associates, Inc. (NEA), a ... one of its portfolio companies, Acclarent, Inc., has ... by Ethicon, Inc., a Johnson & Johnson company, ... (net of estimated cash on hand at time ... designing, developing and commercializing devices that address conditions ...
(Date:12/16/2009)... never felt so good for "The Biggest Loser" Danny ... continuing to make smart choices everyday to help him ... choice that is an important part of living well. ... glass of milk has nine essential nutrients like protein ... pressure, and calcium and vitamin D for strong bones. ...
(Date:12/16/2009)... Dec. 16 As a result of C3: ... new peer reviewed cancer research program is included in ... ,, This new cancer research program will research cancers, ... breast, prostate, lung and ovarian cancer research programs run ... ,, The $15 million in funding for ...
(Date:12/16/2009)... role in reducing inflammation in the lungs , , WEDNESDAY, ... plays a role in inflammation seems to protect the ... who smoke. , Researchers also found that adult smokers ... lower risk of developing chronic obstructive pulmonary disease (COPD), ... "The gene seems to be protective of the lungs ...
(Date:12/16/2009)... omega-3 essential fatty acids commonly found in fatty ... according to research published by the American Psychological ... information-processing problems found in people with schizophrenia; bipolar, ... other afflictions of the nervous system. , ... Neuroscience , provides more evidence that fish is ...
Breaking Medicine News(10 mins):Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:New study links DHA type of omega-3 to better nervous-system function 2
... association exists between depression severity and poor Glycaemic control ... of the diabetics were found having received mental health ... Columbia University's Mailman School of Public Health and College ... 200 Hispanics with diabetes. "We found a steady increase ...
... genetics, more importance is being given to the tendency of ... the same. // A recent study has now shown that ... on dialysis. ,What is even more alarming is ... that can be treated at early stages. Family members of ...
... survival rate of patients with testicular cancer has increased significantly ... now shown that fatherhood is a reachable possibility for many ... the most common form of cancer among men ages 20 ... side than on the left. The cause for the cancer ...
... Research has leaned in a big way towards eating up ... studies presented at the meeting extolled on the virtues of ... experts are now of the view that the best way ... you eat, in other words diet modification may actually add ...
... US and University of Tokyo, Japan have found a faster ... a bird flu outbreak involving mutant strain of virus occurs. ... the avian virus which may be very lethal and may ... University of Wisconsin-Madison, working with Japanese colleagues from the University ...
... an important signaling pathway in prostate cancer cells, thereby ... of Vitamin E // that limits the proliferation of ... study are the first to describe the role of ... TAP in prostate cancer. Expression levels of TAP are ...
Other Medicine News:Health News:Testicular Cancer Patients Have Improved Reproductive Outcomes After Treatment 2Health News:Faster way of producing Bird flu vaccine using Reverse Genetics 2
All Day Comfort for the Lower Body...
All Purpose, General Procedure Apron...
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: